IMM-101

IMM-101
Clinical data
Other names	Mycobacterium obuense (heat-killed)
Identifiers
UNII	IZT740JY57 ;

Last updated June 28, 2025

IMM-101 is an immunomodulatory drug that is being studied to see if it is useful in chemotherapy.^[1] It consists of heat-killed Mycobacterium obuense bacteria. It may have relatively few side effects compared to other drugs.^[2]^[3]

References

↑ Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, et al. (September 2016). "Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer". British Journal of Cancer. 115 (7): 789–796. doi:10.1038/bjc.2016.271. PMC 5046215 . PMID 27599039.
↑ Boseley S (6 September 2016). "New drug 'wakes up' immune system to fight one of deadliest cancers". The Guardian.
↑ Dalgleish V (17 March 2015). "A trial looking at a new type of immunotherapy for cancer of the pancreas that can't be removed with surgery". Cancer Research UK.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, et al. (September 2016). "Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer". British Journal of Cancer. 115 (7): 789–796. doi:10.1038/bjc.2016.271. PMC 5046215 . PMID 27599039.

[2] Boseley S (6 September 2016). "New drug 'wakes up' immune system to fight one of deadliest cancers". The Guardian.

[3] Dalgleish V (17 March 2015). "A trial looking at a new type of immunotherapy for cancer of the pancreas that can't be removed with surgery". Cancer Research UK.

[1]

[2]

[3]